To regrow the human heart had only been a dream, not a possibility before the derivation of human embryonic stem cells (hESC) from the inner cell mass (ICM) or epiblast of the human blastocyst.The hESC cardiac cell therapy derivatives are emerging as a new type of pharmacologic agent of cellular entity in cellbased regenerative medicine because they have direct pharmacologic utility and capacity for human myocardial tissue reconstitution and contractile function restoration that the conventional compound drug of molecular entity lacks.Transforming pluripotent hESCs into fate-restricted cardiac cell therapy derivatives dramatically increases the clinical efficacy of graft-dependent repair and safety of hESC-derived cellular products, bringing cell-based regenerative medicine to a turning point for heart disease and failure. (Xuejun H Parsons,Reviving Cell-Based Regenerative Medicine for Heart Reconstitution with Efficiency in Deriving Cardiac Elements from Pluripotent Human Embryonic Stem Cells)
Free Medical Journals from OMICS Group International has started to disseminate the peer-reviewed scholarly and academic content to scientific community with free access and to provide the unrestricted distribution of the scholarly knowledge under creative commons attribution license for the benefit of humankind. Our free medical journals are completely open access journals and publish high quality articles from the corners of the globe to update the recent developments in the fields of medical sciences. These scholarly journals aim to contribute to the progress and application of scientific discoveries, by providing free access to the research information. The published work reaches the general public and the scientific community immediately after publication, thus providing higher citation rates for the author. Medical Journals are supported by 5000 internationally renowned editorial board members and a high quality review board.
Last date updated on January, 2021